Nabriva Therapeutics Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nabriva Therapeutics stock.
View analyst ratings for Nabriva Therapeutics or view top-rated stocks.

Wall Street analysts have given Nabriva Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nabriva Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Nabriva Therapeutics.

Nabriva Therapeutics plc (NASDAQ:NBRV) released its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.53) EPS for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.14. The biotechnology company had revenue of $2.53 million for the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 81.28% and a negative net margin of 506.93%.
View Nabriva Therapeutics' earnings history.

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NBRV stock has increased by 6.6% and is now trading at $1.29.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued 12 month target prices for Nabriva Therapeutics' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Nabriva Therapeutics' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 365.1% from the stock's current price.
View analysts' price targets for Nabriva Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Nabriva Therapeutics include Harmony Biosciences (HRMY), Madrigal Pharmaceuticals (MDGL), Cerevel Therapeutics (CERE), ADC Therapeutics (ADCT), Supernus Pharmaceuticals (SUPN), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Applied Molecular Transport (AMTI), Arcus Biosciences (RCUS), Constellation Pharmaceuticals (CNST), Y-mAbs Therapeutics (YMAB), Amneal Pharmaceuticals (AMRX), Heron Therapeutics (HRTX), Cytokinetics (CYTK) and NGM Biopharmaceuticals (NGM).
View all of NBRV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Nabriva Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Squarepoint Ops LLC (0.04%), Renaissance Technologies LLC (0.05%), Jane Street Group LLC (0.02%), Dimensional Fund Advisors LP (0.01%) and Virtu Financial LLC (0.01%). Company insiders that own Nabriva Therapeutics stock include Colin Md Broom, Francesco Maria Lavino, Gary Sender, Steven P Gelone and Theodore R Schroeder.
View institutional ownership trends for Nabriva Therapeutics.

NBRV stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Nabriva Therapeutics or view top insider-selling stocks.

NBRV stock was acquired by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Jane Street Group LLC, Dimensional Fund Advisors LP, and Virtu Financial LLC. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Colin Md Broom, Francesco Maria Lavino, and Theodore R Schroeder.
View insider buying and selling activity for Nabriva Therapeutics or or view top insider-buying stocks.

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NBRV stock can currently be purchased for approximately $1.29.

Nabriva Therapeutics has a market capitalization of $456.91 million and generates $5.03 million in revenue each year. The biotechnology company earns $-69,480,000.00 in net income (profit) each year or ($5.20) on an earnings per share basis.

Nabriva Therapeutics employs 72 workers across the globe.

The official website for Nabriva Therapeutics is www.nabriva.com.

Nabriva Therapeutics is headquartered at 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406.

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The biotechnology company can be reached via phone at (531) 649-2000 or via email at [email protected]